Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma

Veterinary Immunology and Immunopathology

Volumn 164, Issue 3-4, 2015, Pages 148-159

  Rue, Sarah M ^a   Eckelman, Brendan P ^a,c   Efe, Jem A ^a   Bloink, Kristin ^b   Deveraux, Quinn L ^a,c   Lowery, David ^b   Nasoff, Marc ^a,d  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b ELANCO ANIMAL HEALTH   (United States)

^c Inhibrx   (United States)

^d COI Pharmaceutical ^*  (United States)

Author keywords

Antibody; Canine; CD20; Immunoglobulin; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1E4; MONOCLONAL ANTIBODY CD20; RITUXIMAB; UNCLASSIFIED DRUG; CD20 ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BEAGLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CHO CELL LINE; CLONING; CROSS REACTION; DNA SEQUENCE; DOG DISEASE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; HEAVY CHAIN; HYBRIDOMA; IMMUNOGENICITY; LEUKOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; ANIMAL; DOG; DOG DISEASES; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; DOG DISEASES; DOGS; HUMANS; LYMPHOMA, B-CELL; RITUXIMAB;

EID: 84926421696     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2015.02.004     Document Type: Article

References (30)

1. Alderson K.L., Sondel P.M. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol. 2011, 2011:379123.
2. Beers S.A., Chan C.H., French R.R., Cragg M.S., Glennie M.J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 2010, 47:107-114.
3. Bergeron L.M., McCandless E.E., Dunham S., Dunkle B., Zhu Y., Shelly J., Lightle S., Gonzales A., Bainbridge G. Comparative functional characterization of canine IgG subclasses. Vet. Immunol. Immunopathol. 2014, 157:31-41.
4. Bubien J.K., Zhou L.J., Bell P.D., Frizzell R.A., Tedder T.F. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 1993, 121:1121-1132.
5. Chardes T., Villard S., Ferrieres G., Piechaczyk M., Cerutti M., Devauchelle G., Pau B. Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. FEBS Lett. 1999, 452:386-394.
6. Cohen S.B., Gaskins C., Nasoff M.S. Generation of a monoclonal antibody agonist to toll-like receptor 4. Hybridoma (Larchmt) 2005, 24:27-35.
7. Day M.J. Clinical Immunology of the Dog and Cat 2012, Manson Publishing Ltd. second ed.
8. Dotan E., Aggarwal C., Smith M.R. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T 2010, 35:148-157.
9. Du J., Wang H., Zhong C., Peng B., Zhang M., Li B., Huo S., Guo Y., Ding J. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J. Biol. Chem. 2007, 282:15073-15080.
10. Faldyna M., Leva L., Knotigova P., Toman M. Lymphocyte subsets in peripheral blood of dogs - a flow cytometric study. Vet. Immunol. Immunopathol. 2001, 82:23-37.
11. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 2008, 16:704-709.
12. Gearing D.P., Virtue E.R., Gearing R.P., Drew A.C. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs. BMC Vet. Res. 2013, 9:226.
13. Impellizeri J.A., Howell K., McKeever K.P., Crow S.E. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet. J. 2006, 171:556-558.
14. Jostock T., Dragic Z., Fang J., Jooss K., Wilms B., Knopf H.P. Combination of the 2A/furin technology with an animal component free cell line development platform process. Appl. Microbiol. Biotechnol. 2010, 87:1517-1524.
15. Jubala C.M., Wojcieszyn J.W., Valli V.E., Getzy D.M., Fosmire S.P., Coffey D., Bellgrau D., Modiano J.F. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet. Pathol. 2005, 42:468-476.
16. Kano R., Inoiue C., Okano H., Yamazaki J., Takahashi T., Watari T., Tokuriki M., Hasegawa A. Canine CD20 gene. Vet. Immunol. Immunopathol. 2005, 108:265-268.
17. Kilpatrick K.E., Wring S.A., Walker D.H., Macklin M.D., Payne J.A., Su J.L., Champion B.R., Caterson B., McIntyre G.D. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997, 16:381-389.
18. Li H., Ayer L.M., Lytton J., Deans J.P. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 2003, 278:42427-42434.
19. Modiano J.F., Breen M., Burnett R.C., Parker H.G., Inusah S., Thomas R., Avery P.R., Lindblad-Toh K., Ostrander E.A., Cutter G.C., Avery A.C. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005, 65:5654-5656.
20. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu. Rev. Med. 2008, 59:237-250.
21. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8:147-156.
22. Pinho S.S., Carvalho S., Cabral J., Reis C.A., Gartner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl. Res. 2012, 159:165-172.
23. Polyak M.J., Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002, 99:3256-3262.
24. Richards K.L., Suter S.E. Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?. Immunol. Rev. 2015, 263:173-191.
25. Rowell J.L., McCarthy D.O., Alvarez C.E. Dog models of naturally occurring cancer. Trends Mol. Med. 2011, 17:380-388.
26. Salfeld J.G. Isotype selection in antibody engineering. Nat. Biotechnol. 2007, 25:1369-1372.
27. Stasi R., Brunetti M., Stipa E., Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004, 103:4424-4428.
28. Tang L., Sampson C., Dreitz M.J., McCall C. Cloning and characterization of cDNAs encoding four different canine immunoglobulin gamma chains. Vet. Immunol. Immunopathol. 2001, 80:259-270.
29. van Meerten T., Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin. Hematol. 2010, 47:199-210.
30. Vlasak J., Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr. Pharm. Biotechnol. 2008, 9:468-481.